The Proteometer™ and Indigo AI will provide in-process analytics to pharmaceutical antibody manufactures.
October 01, 2020
WEST LAFAYETTE, IN – Novilytic, LLC, an Indiana based bio-analytics company that secures lifesaving drugs and medical devices and Indigo BioAutomation, a leader in computational analytics and software automation for the life sciences industry, announced that they have signed a Memo of Understanding to develop Artificial Intelligence for the Novilytic Proteometer.
“The Proteometer™ represents a truly disruptive technology that will allow process research and manufacturing chemists/engineers to monitor and control antibody growth in process. Combining Indigo’s well-respected technologies with the Proteometer will create in-process analytics that do not exist today.”, advised Dr. Fred Regnier, CTO and co-founder.
Novilytic is currently focused on the pharmaceutical bioreactor market that produces monoclonal antibodies, one of the most important biopharmaceuticals used in the treatment of many cancers, diseases, and viruses. The market is hampered as these drugs require extensive post-production testing. Until the Proteometer™, no instrument was available to test antibody purity in process, thus releasing that regulatory (FDA) and monetary burden.
“Indigo's algorithmic approach solves the problem of releasing real-time data from Process Analytical Technologies like the Proteometer and Indigo's use of machine learning techniques can derive actionable information about the state of production systems. This advantage allows process scientists and engineers to have better control over reactors, ensure better quality, and meet regulatory demands of these very complex drugs.“, advised Dr. Randy Julian, the founder and CEO of Indigo BioAutomation.
The Proteometer and Indigo software are developed here in Indiana where they will be manufactured, sold, and serviced on a global basis.
About Novilytic, LLC
Novilytic is a biochemistry analytics company that secures lifesaving drugs and medical devices. The company is backed by very strong partnerships with large analytical companies, AI leaders, and Pharmaceutical consortiums. Our potency is extended by the Novilytic Team which includes multiple Ph.D. Chemists and Engineers who have helped us secure significant patents and other IP. Our business plan will increase those forces to insure we meet customer, market, and regulatory demands. Learn more at: https://www.novilytic.com/
Contact: Paul C. Dreier, BSc., MBA / email: email@example.com / telephone: +1.317.752.3116
About Indigo BioAutomation, Inc.
Indigo BioAutomation provides automated data analysis solutions for complex data problems. They deliver Cloud-based tools that improve quality and eliminate the need for human inspection of laboratory data in a variety of industries. Indigo is working to improve human health through the interpretation of molecular measurement. Learn more at: https://indigobio.com/